Hematopoietic stem cell transplantation is being successfully used to treat a variety of malignant and nonmalignant disorders. This therapy has resulted in an increasing number of survivors who are at risk for adverse long-term outcomes, including the development of second and subsequent malignant neoplasms. We review the incidence and spectrum of posttransplantation malignancies and discuss risk factors and future directions for research.